Amanta Healthcare Limited submitted a regulatory disclosure regarding the outcome of an investor/analyst meeting held on Thursday, July 9, 2026. This communication serves as a follow-up to the company's earlier intimation dated July 6, 2026, which was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The meeting was conducted virtually at 05:00 P.M. with ValPro Capital as the participating investor/analyst firm. Company officials interacted with the participants during this session.
A key disclosure point emphasized that during the interaction, the company representatives shared only publicly available information. The company specifically confirmed that no Unpublished Price Sensitive Information (UPSI) was discussed or shared with the participants.
The disclosure was signed by Dinodia Nikhita, who holds the positions of Company Secretary & Compliance Officer at Amanta Healthcare Limited. The document was digitally signed on July 9, 2026, at 18:07:11 IST.
The company requested both BSE Limited and the National Stock Exchange of India Limited to take this information on record as part of their ongoing compliance with SEBI listing requirements.
Financial Impact
No financial impact disclosed. This is a routine compliance disclosure regarding investor relations activities.